Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of MS14 in Association With Risperidone in Treatment of Schizophrenia: A Double Blind Randomized Control Trial

NCT01083381 is registered in ClinicalTrials.gov with Farzan Institute as lead sponsor.

NCT NCT01083381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01083381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of MS14 in Association With Risperidone in Treatment of Schizophrenia: A Double Blind Randomized Control Trial
Lead sponsor
Farzan Institute
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2010
Completion date
April 30, 2011
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia